Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20413731rdf:typepubmed:Citationlld:pubmed
pubmed-article:20413731lifeskim:mentionsumls-concept:C0001554lld:lifeskim
pubmed-article:20413731lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:20413731lifeskim:mentionsumls-concept:C0033684lld:lifeskim
pubmed-article:20413731lifeskim:mentionsumls-concept:C0022116lld:lifeskim
pubmed-article:20413731lifeskim:mentionsumls-concept:C0027055lld:lifeskim
pubmed-article:20413731lifeskim:mentionsumls-concept:C0205171lld:lifeskim
pubmed-article:20413731lifeskim:mentionsumls-concept:C1292733lld:lifeskim
pubmed-article:20413731pubmed:issue7lld:pubmed
pubmed-article:20413731pubmed:dateCreated2010-6-17lld:pubmed
pubmed-article:20413731pubmed:abstractTextEvasins (chemokine-binding proteins) have been shown to selectively neutralize chemokine bioactivity. We investigated the potential benefits of Evasin-3 on mouse myocardial ischemia/reperfusion injury.lld:pubmed
pubmed-article:20413731pubmed:languageenglld:pubmed
pubmed-article:20413731pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20413731pubmed:citationSubsetIMlld:pubmed
pubmed-article:20413731pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20413731pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20413731pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20413731pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20413731pubmed:statusMEDLINElld:pubmed
pubmed-article:20413731pubmed:monthJullld:pubmed
pubmed-article:20413731pubmed:issn1524-4636lld:pubmed
pubmed-article:20413731pubmed:authorpubmed-author:MachFrançoisFlld:pubmed
pubmed-article:20413731pubmed:authorpubmed-author:ProudfootAman...lld:pubmed
pubmed-article:20413731pubmed:authorpubmed-author:LerchRenéRlld:pubmed
pubmed-article:20413731pubmed:authorpubmed-author:PelliGraziano...lld:pubmed
pubmed-article:20413731pubmed:authorpubmed-author:PellieuxCorin...lld:pubmed
pubmed-article:20413731pubmed:authorpubmed-author:MontessuitChr...lld:pubmed
pubmed-article:20413731pubmed:authorpubmed-author:LengletSébast...lld:pubmed
pubmed-article:20413731pubmed:authorpubmed-author:MontecuccoFab...lld:pubmed
pubmed-article:20413731pubmed:authorpubmed-author:Braunersreuth...lld:pubmed
pubmed-article:20413731pubmed:authorpubmed-author:DeruazMaudMlld:pubmed
pubmed-article:20413731pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20413731pubmed:volume30lld:pubmed
pubmed-article:20413731pubmed:ownerNLMlld:pubmed
pubmed-article:20413731pubmed:authorsCompleteYlld:pubmed
pubmed-article:20413731pubmed:pagination1371-7lld:pubmed
pubmed-article:20413731pubmed:meshHeadingpubmed-meshheading:20413731...lld:pubmed
pubmed-article:20413731pubmed:meshHeadingpubmed-meshheading:20413731...lld:pubmed
pubmed-article:20413731pubmed:meshHeadingpubmed-meshheading:20413731...lld:pubmed
pubmed-article:20413731pubmed:meshHeadingpubmed-meshheading:20413731...lld:pubmed
pubmed-article:20413731pubmed:meshHeadingpubmed-meshheading:20413731...lld:pubmed
pubmed-article:20413731pubmed:meshHeadingpubmed-meshheading:20413731...lld:pubmed
pubmed-article:20413731pubmed:meshHeadingpubmed-meshheading:20413731...lld:pubmed
pubmed-article:20413731pubmed:meshHeadingpubmed-meshheading:20413731...lld:pubmed
pubmed-article:20413731pubmed:meshHeadingpubmed-meshheading:20413731...lld:pubmed
pubmed-article:20413731pubmed:meshHeadingpubmed-meshheading:20413731...lld:pubmed
pubmed-article:20413731pubmed:meshHeadingpubmed-meshheading:20413731...lld:pubmed
pubmed-article:20413731pubmed:meshHeadingpubmed-meshheading:20413731...lld:pubmed
pubmed-article:20413731pubmed:meshHeadingpubmed-meshheading:20413731...lld:pubmed
pubmed-article:20413731pubmed:meshHeadingpubmed-meshheading:20413731...lld:pubmed
pubmed-article:20413731pubmed:meshHeadingpubmed-meshheading:20413731...lld:pubmed
pubmed-article:20413731pubmed:meshHeadingpubmed-meshheading:20413731...lld:pubmed
pubmed-article:20413731pubmed:meshHeadingpubmed-meshheading:20413731...lld:pubmed
pubmed-article:20413731pubmed:meshHeadingpubmed-meshheading:20413731...lld:pubmed
pubmed-article:20413731pubmed:meshHeadingpubmed-meshheading:20413731...lld:pubmed
pubmed-article:20413731pubmed:meshHeadingpubmed-meshheading:20413731...lld:pubmed
pubmed-article:20413731pubmed:meshHeadingpubmed-meshheading:20413731...lld:pubmed
pubmed-article:20413731pubmed:meshHeadingpubmed-meshheading:20413731...lld:pubmed
pubmed-article:20413731pubmed:meshHeadingpubmed-meshheading:20413731...lld:pubmed
pubmed-article:20413731pubmed:meshHeadingpubmed-meshheading:20413731...lld:pubmed
pubmed-article:20413731pubmed:meshHeadingpubmed-meshheading:20413731...lld:pubmed
pubmed-article:20413731pubmed:year2010lld:pubmed
pubmed-article:20413731pubmed:articleTitleSingle administration of the CXC chemokine-binding protein Evasin-3 during ischemia prevents myocardial reperfusion injury in mice.lld:pubmed
pubmed-article:20413731pubmed:affiliationCardiology Division, Department of Medicine, Geneva University Hospital, Foundation for Medical Researches, 64 Avenue Roseraie, 1211 Geneva, Switzerland. fabrizio.montecucco@unige.chlld:pubmed
pubmed-article:20413731pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20413731pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed